Latest Mirum Pharmaceuticals News & Updates

See the latest news and media coverage for Mirum Pharmaceuticals. We track all announcements, press releases, and industry mentions in real time, all in one place.

Mirum Pharmaceuticals

Rare disease biopharmaceutical company

mirumpharma.com

Headquarters: Foster City, United States
Founded year: 2018
Company type: Public company
Number of employees: 450–500
Industry: Pharmaceuticals

Last updated Today

Latest news about Mirum Pharmaceuticals

In short: Mirum Pharmaceuticals achieved positive Phase 2 results for zilurgisertib and volixibat while securing $600 million in debt financing.

Company announcements

July 13 Mirum Pharmaceuticals

Mirum Pharmaceuticals reports inducement grants under Nasdaq rule

The awards include non-qualified stock options and RSUs to six new employees, with shares vesting over three to four years.

June 14 Mirum Pharmaceuticals

Mirum and Incyte announce positive Phase 2 results for zilurgisertib

FDA accepted NDA for zilurgisertib under Priority Review, with PDUFA date September 26, 2026.

June 4 Mirum Pharmaceuticals

Mirum and Incyte announce pivotal zilurgisertib results for ENDO 2026

Results from Cohort 1 of the PROGRESS study underpin the NDA, which has been granted Priority Review with a PDUFA date of September 26, 2026.

May 30 Mirum Pharmaceuticals

Mirum Pharmaceuticals announces new data from rare liver disease programs

Results from VISTAS, AZURE-1, and LIVMARLI studies presented at EASL Congress 2026 show positive efficacy and safety.

Media coverage

July 26 Markets Insider

Mirum Pharmaceuticals Inc.DL-Exch. Notes 2024(29) Bond

The Mirum Pharmaceuticals Inc.-Bond has a maturity date of 5/1/2029 and offers a coupon of 4.0000%. The payment of the coupon will take place 2,0...

July 17 Endpoints News

Midsize biotechs urge White House to drop pricing rules

Midsize biotechs including Neurocrine, Ardelyx, Mirum, Madrigal met White House/HHS officials opposing CMS pricing models GLOBE and GUARD. PhRMA warns of legal battle.

July 8 Barron's

Record merger boom identifies 14 takeover targets

More mergers among brand-name consumer companies seem likely—following a record $2.6 trillion worth of transactions announced in the first half of 2026.

June 25 Yahoo Finance

Is Mirum Pharmaceuticals, Inc. (MIRM) Emerging as a Rare Disease Growth Story After New FOP Data?

We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. Mirum Pharmaceuticals, ...

Never miss news about Mirum Pharmaceuticals

Track Mirum Pharmaceuticals and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Mirum Pharmaceuticals competitors & trending companies

Browse news for competitors to Mirum Pharmaceuticals and other trending companies.